InfuSystem (INFU) Q2 FY26 earnings call

InfuSystem delivered a record revenue quarter, driven by robust growth in its core Oncology business and accelerating expansion in Wound Care, despite the impact of a GE Healthcare contract restructuring. The company achieved significant adjusted EBITDA growth and margin expansion, supported by operational efficiencies and strategic partnerships. Management remains focused on leveraging its new ERP system for further process improvements and maintaining its long-term profitability targets.